MTVA biotech catalysts & pipeline

METAVIA INC · Data as of 2026-10-25

Upcoming catalysts

vanoglipel (DA-1241) — FDA meeting

H2 2026

The Company is currently working to schedule an End-of-Phase 2 meeting with the FDA during the second half of 2026 to discuss the clinical development pathway for the vanoglipel combination therapy.

Source filing

DA-1726 — Topline data

Q4 2026

Her extensive experience leading the clinical development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies, will be invaluable as we plan the next stages of development for DA-1726. Sarah joins MetaVia at an important time as we prepare for the anticipated fourth quarter 2026 topline data readout from Part 3 of our Phase 1 clinical trial of DA-1726, evaluating higher target doses of 48 mg and 64 mg.

Source filing

vanoglipel (DA-1241) — Full data

Q4 2026

We are expecting to finalize the Clinical Study Report of the Phase 2a clinical trial in the fourth quarter of 2026.

Source filing

Explore the free biotech catalyst calendar